Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients,...

COVID-19
Global Cancer Care

Eduardo L. Cazap, MD, PhD, on COVID-19: The View From South America

Eduardo L. Cazap, MD, PhD, of the Sociedad Latinoamericana y del Caribe de Oncología Médica, and an international editor on The ASCO Post Editorial Board, talks about the sit...

Global Cancer Care
COVID-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they tr...

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 4

For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?

Recorded April 24, 2020.

Lymphoma
COVID-19

Mehdi Hamadani, MD: In My Experience Question 3

During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma?

Recorded April 21, 2020.

Advertisement

Advertisement



Advertisement